Toukam, Marie http://orcid.org/0000-0001-7040-712X
Wuerthner, Jens
Havenith, Karin
Hamadani, Mehdi
Caimi, Paolo F.
Kopotsha, Tim
Cruz, Hans G.
Boni, Joseph P.
Funding for this research was provided by:
ADC Therapeutics
Article History
Received: 14 June 2022
Accepted: 18 October 2022
First Online: 4 November 2022
Declarations
:
: M Toukam is currently employed and a current equity holder at ADC Therapeutics America, Inc., a publicly traded company. J Wuerthner is currently employed and a current equity holder at ADC Therapeutics SA, a publicly traded company. K Havenith is currently employed and a current equity holder at ADC Therapeutics (UK) Ltd, a publicly traded company. M Hamadani reports consultancy with Janssen R&D, Incyte Corporation, ADC Therapeutics, Celgene Corporation, Pharmacyclics, Omeros, AbGenomics, Verastem, TeneoBio, Seagen, Genmab, Novartis, and Kite; membership on an entity’s board of directors or advisory committees for ADC Therapeutics; research funding from Takeda Pharmaceutical Company, Spectrum Pharmaceuticals, and Astellas Pharma; and speakers bureau memberships for Sanofi Genzyme, AstraZeneca, BeiGene, and Kite. PF Caimi reports advisory board memberships for Amgen, Bayer, Kite Pharma, ADC Therapeutics, Novartis, and Genentech; research funding for ADC Therapeutics and Genentech; and speakers bureau membership for Celgene. T Kopotsha is currently employed and a current equity holder at ADC Therapeutics (UK) Ltd, a publicly traded company. HG Cruz is currently employed and a current equity holder at ADC Therapeutics SA, a publicly traded company. JP Boni is currently employed and a current equity holder at ADC Therapeutics America, Inc., a publicly traded company.